A meta-analysis of 20 clinical trials of anti-PD-1/PD-L1 therapy in melanoma, non-small cell lung cancer, and renal cell carcinoma patients noted that 1% was among the most frequently used cutoff values for PD-L1 [35]. This evidence concerns the gene CD274 and renal cell carcinoma.